OMED.JK(OMED.JK)
OMED.JK
No analyst ratings available
No analyst price targets available for OMED.JK
Analyst coverage may not be available for this symbol
Earnings surprise history unavailable.
No recent analyst actions
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $2.40T | $2.73T | $3.08T |
| Low | $2.38T | $2.67T | $3.01T |
| High | $2.41T | $2.79T | $3.15T |
| EBITDA Avg | $598.28B | $681.47B | $769.40B |
| Low | $595.15B | $666.01B | $751.23B |
| High | $601.42B | $696.93B | $787.57B |
| EBIT Avg | $559.55B | $637.35B | $719.59B |
| Low | $556.62B | $622.90B | $702.60B |
| High | $562.49B | $651.81B | $736.59B |
| Net Income Avg | $406.50B | $465.50B | $529.00B |
| Low | $405.67B | $463.53B | $527.67B |
| High | $454.23B | $520.76B | $602.64B |
| EPS Avg | $15.90 | $18.20 | $20.90 |
| Low | $15.00 | $17.14 | $19.51 |
| High | $16.80 | $19.26 | $22.29 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 | 2 / 2 |
| Metric | Q1 2027 | Q4 2027 |
|---|---|---|
| Revenue Avg | $427.00B | $490.00B |
| Low | $427.00B | $490.00B |
| High | $427.00B | $490.00B |
| EBITDA Avg | $106.67B | $122.40B |
| Low | $106.67B | $122.40B |
| High | $106.67B | $122.40B |
| EBIT Avg | $99.76B | $114.48B |
| Low | $99.76B | $114.48B |
| High | $99.76B | $114.48B |
| Net Income Avg | — | — |
| Low | — | — |
| High | — | — |
| EPS Avg | — | — |
| Low | — | — |
| High | — | — |
| Analysts (Rev / EPS) | 1 / — | 1 / — |